Gupta Deepak K, Giugliano Robert P, Ruff Christian T, Claggett Brian, Murphy Sabina, Antman Elliott, Mercuri Michele F, Braunwald Eugene, Solomon Scott D
Vanderbilt Heart and Vascular Institute, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University Medical Center, Nashville, Tennessee.
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
J Am Soc Echocardiogr. 2016 Jun;29(6):537-44. doi: 10.1016/j.echo.2016.03.004. Epub 2016 Apr 20.
Atrial fibrillation (AF) is associated with increased risk for thromboembolism and death; however, the relationships between cardiac structure and function and adverse outcomes among individuals with AF are incompletely understood.
The Effective Anticoagulation with Factor Xa Next Generation in AF-Thrombolysis in Myocardial Infarction 48 study tested the once-daily oral factor Xa inhibitor edoxaban in comparison with warfarin for the prevention of stroke (ischemic or hemorrhagic) or systemic embolism in 21,105 subjects with nonvalvular AF and increased risk for thromboembolic events (CHADS2 score ≥ 2). In a prospective substudy of 971 subjects who underwent transthoracic echocardiography at baseline, Cox proportional hazards models were used to evaluate associations between cardiac structure and function and the risks for death and thromboembolism (ischemic stroke, transient ischemic attack, or systemic embolism).
Over a median follow-up period of 2.5 years, 89 deaths (9.2%) and 48 incident thromboembolic events (4.9%) occurred in 971 subjects. In models adjusted for CHADS2 score, aspirin use, and randomized treatment, larger left ventricular (LV) end-diastolic volume index (hazard ratio per 1 SD [12.9 mL/m(2)], 1.49; 95% CI, 1.16-1.91) and higher LV filling pressures measured by E/e' ratio (hazard ratio per 1 SD [4.6], 1.32; 95% CI, 1.08-1.61) were independently associated with increased risks for death. E/e' ratio > 13 significantly improved the prediction of death beyond clinical factors alone. No features of cardiac structure and function were independently associated with thromboembolism in this population. Findings were similar when adjusted for CHA2DS2-VASc score in place of CHADS2 score.
In a contemporary population of patients with AF at increased risk for thromboembolic events, larger LV size and higher filling pressures were significantly associated with increased risk for death, but neither left atrial nor LV measures were associated with thromboembolic risk. LV size and filling pressures may help identify patients with AF at increased risk for death.
心房颤动(AF)与血栓栓塞和死亡风险增加相关;然而,AF患者心脏结构和功能与不良结局之间的关系尚未完全明确。
在AF-心肌梗死溶栓48研究中,对21,105例非瓣膜性AF且血栓栓塞事件风险增加(CHADS2评分≥2)的受试者,比较每日一次口服Xa因子抑制剂依度沙班与华法林预防中风(缺血性或出血性)或全身性栓塞的效果。在一项对971例基线时接受经胸超声心动图检查的受试者进行的前瞻性亚研究中,采用Cox比例风险模型评估心脏结构和功能与死亡及血栓栓塞(缺血性中风、短暂性脑缺血发作或全身性栓塞)风险之间的关联。
在971例受试者中,中位随访期2.5年时,发生89例死亡(9.2%)和48例血栓栓塞事件(4.9%)。在根据CHADS2评分、阿司匹林使用情况和随机治疗进行校正的模型中,左心室(LV)舒张末期容积指数较大(每1标准差[12.9 mL/m²]的风险比为1.49;95%CI,1.16 - 1.91)以及通过E/e'比值测量的较高LV充盈压(每1标准差[4.6]的风险比为1.32;95%CI,1.08 - 1.61)与死亡风险增加独立相关。E/e'比值>13显著改善了仅根据临床因素对死亡的预测。在该人群中,心脏结构和功能的特征均与血栓栓塞无独立关联。用CHA2DS2-VASc评分替代CHADS2评分进行校正时结果相似。
在当代血栓栓塞事件风险增加的AF患者人群中,较大的LV大小和较高的充盈压与死亡风险增加显著相关,但左心房和LV指标均与血栓栓塞风险无关。LV大小和充盈压可能有助于识别AF死亡风险增加的患者。